Oppenheimer analyst Hartaj Singh downgraded Moderna (NASDAQ: MRNA) from Outperform to Perform.The analyst comments "MRNA's R&D Day highlights evolving clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE